Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
biotech
national blog main
national top stories
boston blog main
boston top stories
clinical trials
san francisco top stories
boston
cancer
fda
national
new york blog main
new york top stories
san francisco blog main
digital health
europe top stories
san diego blog main
san diego top stories
texas blog main
texas top stories
akcea therapeutics
alnylam pharmaceuticals
arena pharmaceuticals
barry greene
beam therapeutics
billy dunn
biogen
biologic drugs
biotech week boston
boston university
boston xcon
boulder/denver blog main
boulder/denver top stories
boulder/denver xcon
bristol-myers squibb
broad institute
bwb
cancer immunotherapy
cardiovascular disease
What
medicine
7
×
patients
7
×
drug
fda
cancer
friday
market
transformed
ago
allison
alnylam
approve
approved
atrophy
awaits
award
benefiting
biologic
biological
boston
bottleneck
cancers
center
clinical
coming
community
complexity
countless
crossed
daily
decades
decision
development
diagnostics
digital
discovered
dramatically
eisai
evrysdi
fight
Language
unset
Current search:
xconomy.com
×
medicine
×
patients
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com
5 years ago
Digital Tools, Online Community & More: Patient Partnership Award Finalists
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority